Product Description
AT-752 is being developed by Atea for the treatment of Dengue Infection. (Sourced from: https://clinicaltrials.gov/ct2/results?cond=&term=AT-752&cntry=&state=&city=&dist=)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: Fast Track - Dengue *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Atea
Company Location: BOSTON MA 02110
Company CEO: Jean-Pierre Sommadossi
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Dengue
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AT-02A-003 | P1 |
Terminated |
Dengue |
2023-03-16 |
70% |
| AT-02A-002 | P2 |
Terminated |
Dengue |
2023-01-19 |
|
| AT-02A-001 | P1 |
Completed |
Dengue |
2021-11-14 |
70% |